How Novartis’s Promacta, Votrient, and Jakavi Performed in 1H17

In 1H17, Novartis’s (NVS) Promacta/Revolade reported revenues of around $385 million, which reflected ~33% growth on a year-over-year (or YoY) basis. In 2Q17, Promacta/Revolade generated revenues of around $210 million, which is ~33% growth on a YoY basis, and ~20% growth on a quarter-over-quarter basis.

Promacta is used for the treatment of individuals with chronic immune (idiopathic) thrombocytopenia (or ITP) who didn’t have an adequate response to corticosteroids, immunoglobulins, or splenectomy. Promacta is also used for the treatment of individuals with chronic hepatitis C for maintenance of interferon-based therapy and individuals with severe aplastic anemia who didn’t respond adequately to immunosuppressive therapy. Promacta competes with Amgen’s (AMGN) Nplate in the chronic ITP drugs market.

In 1H17, Votrient reported revenues of around $382 million, which is ~8% growth on a YoY basis. In 2Q17, Votrient generated revenues of around $204 million, which is ~9% growth on a YoY basis and ~15% growth on a quarter-over-quarter basis. Votrient is used for the treatment of individuals with advanced renal cell carcinoma and advanced soft tissue carcinoma. Votrient competes with Bayer’s (BAYZF) Nexavar (sorafenib), Pfizer’s (PFE) Sutent (sunitinib), and Torisel (temsirolimus) in the renal carcinoma drugs market.

In 1H17, Jakavi reported revenues of around $348 million, which reflected ~29% growth on a YoY basis. In 2Q17, Jakavi generated revenues of around $186 million, which is ~27% growth on a YoY basis and 15% growth on a quarter-over-quarter basis.

Jakavi is used for the treatment of individuals with myelofibrosis. The drug is also used for the treatment of individuals with polycythaemia vera who are intolerant or resistant to hydroxyurea.

Sales growth in Novartis’s Promacta, Votrient, and Jakavi could boost the First Trust Value Line Dividend Index Fund (FVD). Novartis makes up about ~0.51% of FVD’s total portfolio holdings.